Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
540 people get OPTR articles and Market Currents by email alert.
Get email alerts on OPTR »
FOCUS
|
PRO
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
Optimer Pharmaceuticals' Encouraging FDA NewsZacks Investment Research • Tue, Jul 5, 2011 -
-
-
-
-
-
Promising Year Ahead for Optimer PharmaZacks Investment Research • Mon, Jun 29, 2009
-
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
-
-
-
-
-
-
-
-
Fund Holdings For 3 Healthcare Stocks, And 4 Other SellsGuruFundPicks • Mon, Jun 18, 2012
-
-
-
-
-
9 Rallying Biotech Stocks Being Snapped Up By Hedge FundsKapitall • Tue, May 15, 2012
-
-
5 Hedge Fund Biotech Stock Picks With Significant Short CoveringKapitall • Tue, Apr 24, 2012
-
Optimer Pharmaceuticals, Inc. Q4 2008 Earnings Call TranscriptWed, Mar 11, 2009
-
Optimer Pharmaceuticals, Inc. Q4 2007 Earnings Call TranscriptSun, Apr 27, 2008
-
PR Newswire (May 13, 2013)
-
PR Newswire (May 9, 2013)
-
PR Newswire (Apr 26, 2013)
-
PR Newswire (Mar 15, 2013)
-
PR Newswire (Feb 28, 2013)
-
PR Newswire (Feb 27, 2013)
-
PR Newswire (Feb 7, 2013)
-
PR Newswire (Feb 1, 2013)
-
PR Newswire (Jan 7, 2013)
-
PR Newswire (Dec 24, 2012)
-
PR Newswire (Dec 20, 2012)
-
PR Newswire (Dec 5, 2012)
-
PR Newswire (Nov 7, 2012)
-
PR Newswire (Nov 1, 2012)
OPTR vs. ETF Alternatives
Company Description
Currently, there's no company description for OPTR.
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Thursday, May 9, 4:11 PM Optimer Pharmaceuticals (OPTR): Q1 EPS of -$0.65 misses by $0.06. Revenue of $19.4M misses by $1.69M. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Thursday, May 9, 12:10 AM Notable earnings after Thursday’s close: AGO, AIRM, AL, ALIM, ANAC, ASYS, AUQ, BCEI, BID, BPZ, CALL, CPE, DAR, EGY, ET, FTK, FXEN, GXP, KTOS, LLNW, MBI, MCP, MDRX, MDVN, NGVC, NVDA, OPTR, PANL, PCLN, PDLI, PSA, RNDY, SF, SLXP, SQNM, TNGO, UBNT, ZGNX Comment! [Earnings]
- Wednesday, May 8, 5:35 PM Notable earnings after Thursday’s close: AGO, AIRM, AL, ALIM, ANAC, ASYS, AUQ, BCEI, BID, BPZ, CALL, CPE, DAR, EGY, ET, FTK, FXEN, GXP, KTOS, LLNW, MBI, MCP, MDRX, MDVN, NGVC, NVDA, OPTR, PANL, PCLN, PDLI, PSA, RNDY, SF, SLXP, SQNM, TNGO, UBNT, ZGNX Comment! [Earnings]
- Thursday, February 28, 4:23 PM Optimer Pharmaceuticals (OPTR): Q4 EPS of $0.02. Revenue of $19.5M beats by $1.45M. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Thursday, February 28, 12:10 AM Notable earnings after Thursday’s close: AIRM, AL, ALSK, BID, CLNE, CPNO, CRM, DECK, DRH, ENDP, GPS, GXP, HTGC, JOE, KOG, KYAK, MCP, MDR, MDVN, MENT, MTZ, MXWL, NGD, NOG, OPTR, OVTI, PANW, RNDY, RST, SD, SLXP, SONS, SPLK, SSRI, TEG, TESO, UHS, WR, XTEX, YOKU Comment! [Earnings]
- Wednesday, February 27, 5:35 PM Notable earnings after Thursday’s close: AIRM, AL, ALSK, BID, CLNE, CPNO, CRM, DECK, DRH, ENDP, GPS, GXP, HTGC, JOE, KOG, KYAK, MCP, MDR, MDVN, MENT, MTZ, MXWL, NGD, NOG, OPTR, OVTI, PANW, RNDY, RST, SD, SLXP, SONS, SPLK, SSRI, TEG, TESO, UHS, WR, XTEX, YOKU 1 Comment [Earnings]
- Wednesday, February 27, 10:31 AM Optimer Pharmaceuticals (OPTR +15%) says its board of directors has begun exploring a full range of strategic alternatives and has engaged JPMorgan and Centerview Partners as financial advisers. The board stated however, that there are no assurances that the review will result in any action and that there would be no further comment on the process until it's completed. The company also preannounced Q4 results of $0.02 per share, and appointed its chairman, Dr. Henry McKinnell, as CEO. Comment! [Healthcare, Earnings, On the Move]
- Wednesday, February 27, 8:28 AM Optimer Pharmaceuticals, Inc. (OPTR): Q4 EPS of $0.02 may not be comparable to consensus of by -$0.38. Gross product sales of $21.3M. Shares +11.5% premarket. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Thursday, November 1, 2012, 5:15 PM Optimer Pharmaceuticals (OPTR): Q3 EPS of -$0.56 beats by $0.08. Revenue of $17.9M (+6.1% Y/Y) beats by $1.9M. (PR) Comment! [Earnings, Healthcare]
- Tuesday, July 31, 2012, 5:43 PM Optimer Pharma (OPTR): Q2 EPS of -$0.01 beats by $0.06. Revenue of $49.8M (+150809.1% Y/Y) beats by $0.33M. Shares -4.8% AH. (PR) Comment! [Earnings, Healthcare, On the Move]
- Thursday, May 10, 2012, 4:28 PM Optimer Pharmaceuticals (OPTR): Q1 EPS of -$0.23 may not be comparable to consensus of $-0.40. Revenue of $14.4M (-79.2% Y/Y) misses by $14M. (PR) Comment! [Earnings, Healthcare]
- Wednesday, March 7, 2012, 6:01 PM More on Optimer Pharmaceuticals (OPTR): Q4 beats revenue expectations as the early launch of its new drug Dificid adds $11M in sales to its top line. Shares +0.9% AH. Comment! [Healthcare, Earnings]
- Wednesday, March 7, 2012, 5:25 PM Optimer Pharmaceuticals (OPTR): Q4 EPS of $0.29 may not be comparable to consensus of $0.51. Revenue of $64.6M beats by $21M. Shares +0.9% AH. (PR) Comment! [Earnings, Healthcare]
- Thursday, November 3, 2011, 5:16 PM Optimer Pharmaceuticals (OPTR) trades lower in the post-session after reporting a wider than expected Q3 loss. SG&A expenses jumped fourfold Y/Y to $26.9M, compared to $4.8M for the prior year, primarily due to its infrastructure build-up and marketing expenses related to the launch of its blockbuster drug DIFICID. Shares -7.8% AH. Comment! [Earnings, Healthcare]
-
Ryan Mallory
Fuinhaz Setups for February 27 2013 | $BBRY $CCUR $DLTR $OPTR $ZAGG http://bit.ly/YXtYkH - View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
LifeSci Advisors
OPTR - I just posted a survey of physicians on their expected use of DIFICID on my website: http://bit.ly/nEORWJ/ - View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
LATEST REPLIES